)
Pay in 4 interest-free payments of $6.21 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
And lets face it, schedules are unpredictable and sometimes we'll need to go through the drive-thru
This is not exceptional - it applies broadly across the sector
Additional information Competing interests The author declares that he has no competing interests
Who Should Pay Attention to This Research This trial is most immediately relevant to: Older adults with known risk factors for cognitive decline particularly those with obesity, type 2 diabetes, high blood pressure, or cardiovascular disease who are also candidates for GLP-1 therapy Researchers and clinicians working at the intersection of metabolic health and cognitive aging People currently taking GLP-1 medications for diabetes or obesity who have wondered whether the drugs may offer cognitive benefits Caregivers and family members of older adults who are monitoring cognitive health and looking for potential preventive strategies Symptoms and Warning Signs to Watch For The PROTECT-Cog Study is designed for prevention it targets people who are at risk for cognitive decline but have not yet been diagnosed with dementia
Isolation of intestinal epithelial cells (IECs) and lamina propria mononuclear cells (LPMCs) Murine IECs and LPMCs were obtained from the colon and ileum as previously described 40
has received funding from AstraZeneca, Merck Sharp & Dohme and Novartis
US$ 22.63
US$ 25.78
US$ 29.93
